Drug: Lenalidomide (Revlimid, Celgene)
Status: Approved for use as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HCT) in patients with MM who received at least 1 prior therapy
Significant Data:
- First and only treatment approved for maintenance following auto-HSCT
- Updated data from 2 large, randomized controlled studies demonstrated median progression-free survival advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving lenalidomide compared